Skip to main content

How Reliable Is Cannabis DUII Technology?

One of the most common talking points for cannabis opponents is the claim that if cannabis laws are reformed there will be mayhem on public roadways.

The ‘stoned driver epidemic’ doomsday prediction is very popular among people and organizations that campaign and lobby against cannabis reform all over the globe.

No country is immune to the phenomenon. If cannabis reform is being explored, cannabis opponents will come from all over the place to parrot this talking point.

With more countries successfully implementing cannabis reform policies, this talking point is becoming less effective since the doomsday predictions are not becoming reality.

However, cannabis is still an intoxicating substance, and driving under the influence is a very serious issue that deserves constructive conversations and solutions that are based on science.

As countries around the world try to adopt sensible ways to prevent cannabis DUIIs, breathalyzer technology is a popular option for international lawmakers. 

Cannabis Breathalyzers – Effective Technology Or Junk Science?

People that are not familiar with cannabis science often make the false assumption that cannabis intoxication can be effectively measured using a breathalyzer device.

It’s easy to understand why people make that false assumption. After all, breathalyzer technology is very effective at determining if a person is too intoxicated from alcohol consumption to safely operate a motor vehicle on a public roadway.

Unfortunately, the same is not true for cannabis consumption.

All cannabis breathalyzers on the market right now can detect the presence of cannabis, yet they cannot determine if the subject of the breathalyzer is intoxicated or not at the time of the test.

Cannabis affects different people in different ways. An infrequent cannabis user can consume an edible with 5 mgs of THC in it and be too impaired to safely operate a motor vehicle.

A user that consumes cannabis on a frequent basis can consume significantly more than 5 mgs of THC and be able to easily operate a motor vehicle in a safe manner.

Cannabis stays in a person’s system for a long time, especially when the person is a frequent cannabis consumer. 

A breathalyzer may detect cannabis use by a person that occurred well before the person operated a motor vehicle. 

Conversely, a breathalyzer may not detect cannabis use by a newbie since the driver consumed such a small amount of THC, even though the driver may be too impaired to drive at the time of the test.

Canadian Researchers Look At Cannabis Impairment And Motor Vehicle Operation

A group of researchers in Canada recently conducted a double-blind, placebo-controlled clinical trial in which cannabis consumers ‘were randomized with a 2:1 allocation ratio to receive active (12.5% THC) or placebo (0.009% THC) cannabis.’ 

Study participants were then split into two groups – low and high THC, as measured by concentrations of THC in their blood at the time of the trial. 

The participants then performed simulated driving tasks and were assessed 30 minutes, 24 hours, and 48 hours after consuming cannabis.

Researchers concluded the following:

Ninety-six participants were randomized, and 91 were included in the final analysis (30 high THC, 31 low THC, 30 placebo). Mean speed (but not lateral control) significantly differed between groups 30 minutes after smoking cannabis (p ≤ 0.02); low and high THC groups decreased their speed compared to placebo. Heart rate, VAS drug effect and drug high increased significantly immediately after smoking cannabis and declined steadily after that. There was little evidence of residual effects in any of the measures.

The lack of residual effects from cannabis consumption on the drivers in the trial is significant from a DUI policy perspective.

If a cannabis breathalyzer only measures the presence of THC, and not how long ago the consumption occurred or if the consumption caused impairment, the breathalyzer results are basically useless.

Proving Impairment Is Vital For Effective Public Policy And Safety

Responsible members of society want their public roadways to be safe, and responsible cannabis consumers are a subset of that group.

A responsible cannabis consumer does not operate a motor vehicle when impaired and does not want to be lumped in with irresponsible cannabis consumers that get behind the wheel when they shouldn’t.

Because of that, responsible cannabis consumers are helping lead the charge when it comes to developing effective ways of detecting cannabis impairment.

Simply detecting whether or not cannabis use has occurred is not enough. The same is true for measuring metabolized THC in a person’s system.

A much more effective approach is conducting field sobriety tests in a way that incorporates effective technology.

An example of such technology is the Canary App which was developed by NORML. The Canary app ‘combines decades of research and experience, specialized mental and physical performance tests, and sophisticated analysis to accurately measure impairment due to alcohol, medication, fatigue and even the subtle impact of marijuana.’

Performance test technology accounts for a person’s cannabis tolerance level and measures cannabis impairment far more accurately than a breathalyzer that merely detects the presence of THC.

Cannabis DUI laws need to be based on science, not political views, and the technology used by enforcement agencies around the world is obviously part of that.

As lawmakers in countries around the globe continue to explore cannabis reform, effective cannabis DUI detection technology needs to be a top priority.

UK Researchers To Examine Whether CBD Can Help Parkinson’s Patients

Scientists in the UK have announced that they will be launching the largest study to date that looks at cannabidiol (CBD) and if it can be an effective treatment for Parkinson’s disease.

Over 10 million people worldwide suffer from Parkinson’s. A number of personal patient experiences suggest that the cannabis plant can be an effective treatment for Parkinson’s, however, a lot of questions have so far gone unanswered from a research standpoint.

Hopefully the results of this study will help reduce the stigma associated with cannabis, be used as a foundation for continued research, and ultimately help patients across the globe that suffer from Parkinson’s.

To learn more about what the study will involve, including how many patients will be participating, check out our article on Cannabis & Tech Today.

Sign Up To Receive The International Cannabis Chronicle Newsletter

These are truly exciting times for all things cannabis. Cannabis policy reform is sweeping the globe, the cannabis industry is growing at an epic rate, and major cannabis culture news is occurring at an increasing pace.

It can be very difficult to stay up-to-date on everything that is happening in the cannabis world with so much going on at all hours of the day. Cannabis has gone mainstream, and the rise in the level of acceptance of cannabis in society has been paralleled by an increase of news coverage that touches on topics and situations that are not necessarily that important in the grand scheme of things.

For many cannabis consumers, entrepreneurs, and policymakers it can be exhausting to try to sort out the less important stories from the truly important ones due to so much cannabis media white noise. However, at the same time, it is vital for people in the cannabis community at all levels to stay on top of things. It’s a very frustrating catch-22.

To help address the problem the International Cannabis Business Conference launched a new e-mail newsletter, the International Cannabis Chronicle, which covers the most important cannabis news and developments from around the globe.

International Cannabis Chronicle is delivered straight to subscribers’ e-mail inboxes once a week. It’s an extremely convenient way to stay up to-to-date on the most important cannabis information.

If staying up to speed on the biggest cannabis stories is important to you, make sure to sign up to receive the International Cannabis Chronicle newsletter today. You will be glad that you did!

ICC Mailchimp Masthead For Blogs

Cannabinoid Conference 2019 Is Coming To Berlin October 31 – November 2

Cannabinoid Conference 2019 is coming to Berlin, Germany October 31 to November 2. The event is the leading international meeting on medical uses of cannabis and cannabinoids and is hosted by the International Association for Cannabinoid Medicines (IACM).

We are in the midst of a truly amazing era for cannabis research and medicine. Cannabis reform is sweeping the globe, which is creating tremendous opportunities for cannabis entrepreneurs and scientists. The rise of the legal cannabis industry is resulting in an ever-growing demand for cannabis research.

Speakers and presenters at Cannabinoid Conference will be covering the latest results and data from their cutting-edge cannabis trials, studies, and investigations. If you are looking to learn more about cannabis research and network with the leading minds on cannabis science there is no better place to be between October 31 and November 2 than in Berlin, Germany at Cannabinoid Conference 2019.

“When we started our conferences about 20 years ago they were kind of “family meetings” of eminent scientists and clinicians active in the field of the medical use of cannabis and cannabinoids. This family has considerably grown in recent years and we were happy to gradually open the conference to an increasing number of healthcare professionals around the world interested in learning from recent scientific advances and practical knowledge of their experienced colleagues.” Dr. Franjo Grotenhermen, Executive Director of the IACM, told the International Cannabis Business Conference.

Cannabinoid Conference 2019 speakers will include:

  • Arno Hazekamp – Cannabis biochemist Hazekamp Herbal Consulting
  • Attila Olah – University of Debrecen
  • Bonni Goldstein – Medical Director Canna-Centers
  • Carola Perez – President Observatorio Espanol de Cannabis Medicinal
  • Christian Kessler – Immanuel Hospital Berlin
  • Daniela Eigenmann – Deputy Pharmacist Bahnhof Apotheke Langnau
  • Daniele Piomelli – Distinguished Professor UCI Center for the Study of Cannabis
  • Raquel Peyraube – Uruguayian Society of Endocannabinology (SUEN)
  • Ethan Russo – ICCI
  • Franjo Grotenhermen – Executive Director International Association for Cannabinoid Medicines
  • Guillermo Velaso – Associate Professor Complutense University
  • Ilya Reznik – MaReNa Diagnostic and Consultic Center
  • Javier Fernandez-Ruiz – Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Madrid
  • José Alexandre Crippa – Full Professor University of São Paulo
  • Ken Mackie – Indiana University, Bloomington
  • Kirsten Müller-Vahl – Hannover Medical School
  • Mario van der Stelt – Professor and Chair of the Department of Molecular Physiology Leiden University
  • Mark Ware – Chief Medical Officer Canopy Growth Corporation
  • Michael Krawitz – Executive Director of Veterans For Medical Cannabis Access
  • Roger Pertwee – Emeritus Professor University of Aberdeen
  • Ziva Cooper – Research Director, Associate Professor UCLA Cannabis Research Initiative

The robust event schedule will cover a number of topics, all of which are very timely. Cannabinoid Conference 2019 is going to provide an invaluable level of education and information, and will also be an amazing place to network.

There will be simultaneous translation from English into German on the first day. Day one of the conference is a tutorial day with reviews and practical information for physicians.

A reduced fee for the event is available for students and participants from developing countries. The conference offers a day pass option (first day only) in addition to a full conference admission option.

The IACM will honor four people for their major contributions to cannabinoid research and/or to the re-introduction of cannabis into modern medicine with the IACM Award as part of the conference.

When: October 31 – November 2
Where: Estrel Hotel, Berlin, Germany
Purchase tickets: http://cannabinoidconference.org/registration

About Cannabinoid Conference 2019

The first Conference on Cannabinoids took place in Berlin in 2001 and was organized by the International Association for Cannabinoid Medicines. Since the inaugural conference, the event has been held in Cologne, Leiden, Bonn, and Sestri Levante. The 10th conference, Cannabinoid Conference 2019, will be the first time that the event has been held in Berlin since 2001. Berlin is the cannabis capital of Europe and is the perfect setting for Cannabinoid Conference 2019. To find out more information about Cannabinoid Conference 2019 go to: http://cannabinoidconference.org/

About the International Association for Cannabinoid Medicines

The International Association for Cannabinoid Medicines (IACM) was founded in 2000. The aim of the association is to advance knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics especially with regard to their therapeutic potential. The IACM is the most respected international association on cannabis and cannabinoids in medicine. Former chairmen and chairwomen included Raphael Mechoulam, Mark Ware, Roger Pertwee, Manuel Guzman, Franjo Grotenhermen, Ethan Russo and Kirsten Mueller-Vahl. For more information about the International Association for Cannabinoid Medicines go to: https://www.cannabis-med.org/

 

cannabinoid conference

How Worried Should Cannabis Consumers Be About Vape Cartridges?

The United States has been in the middle of a cannabis vape pen hysteria of sorts for the last week or two. Mainstream media and cannabis opponents seem to be obsessed with the story, insinuating that full blame for the unfortunate deaths that have occurred should be placed completely on cannabis vape pen cartridges.

Every one of the deaths is sad and unfortunate, which is why it has been frustrating for the cannabis community to see many mainstream media outlets and cannabis opponents using the deaths of these individuals to help spread misleading anti-cannabis propaganda.

In recent weeks hundreds of illnesses and half a dozen deaths have been reported across the country, with e-cigarette device usage being pointed to as the likely cause. Some cases involve consumers that have reported using cannabis vape pen cartridges and some involve consumers that reported having only used nicotine-based vaping products.

For whatever reason, THC vape pen cartridges have largely become the focus of mainstream media coverage and accusations from opponents. The fact of the matter is that no one at this point is 100% positive what is causing the illnesses and deaths. Consumers and cannabis companies have to wait for more information to become known.

As previously mentioned, some of the cases involve THC cartridges and some do not. Some cases involve the dilutant additive vitamin E acetate and some do not. Vitamin E acetate and other additives are the most likely suspect, and if that proves to be true, then THC has nothing to do with the situation other than the cannabinoid was also present (in some of the cases).

Illegal, unregulated cannabis cartridges have been flooding the United States, especially in illegal jurisdictions. It’s easy to understand why vape pen cartridges are popular among consumers – they are very convenient, indiscrete, and easy to pack around and use. However, for some consumers, those illegal cartridges have come at a terrible cost to their personal health, and in certain cases, potentially their lives.

When someone purchases a cannabis vape pen cartridge from an unregulated source, there’s no telling what could be contained inside of the cartridge. It’s not the THC that is the issue, it’s whatever else may be in the cartridge. The list of ingredients may or may not even include THC.

Even from regulated sources, there are a lot of compounds that can be used that are not prohibited, including dilutants that are used to make the vape pen oil thinner and therefore easier for devices to turn into vapor.

Consumers should definitely be concerned about vape pen cartridges, and about what they inhale in general. However, that concern needs to be tempered. If you live in an illegal state, you should probably avoid vape pen cartridges altogether since there’s no real way to know what is inside of them.

People may claim to have acquired the cartridges from regulated sources, but that is not always the case, with the most obvious sign being that the packaging has cartoon characters on it. Packaging that could be appealing to children is not allowed in legal markets.

For consumers that purchase vape pen cartridges from legal, regulated dispensaries where they live the best approach is to know where the oil inside of the cartridge came from, what ingredients were used, and specifically if any additives have been put into the cartridge such as ‘natural terpenes’ or dilutants.

Terpenes can be sourced from something natural but that doesn’t necessarily mean that they are safe. After all, you inhale it in vapor form if you are consuming it via a vape pen cartridge, and not eating it in its original form. That’s not to say that every additive is unsafe, but until more research is conducted and definitive scientific conclusions are reached it’s best to err on the side of caution.

***

About the International Cannabis Business Conference

International Cannabis Business Conference events are the premier cannabis events for entrepreneurs across the globe. With events in Canada, the United States, Switzerland, Spain, and Germany the International Cannabis Business Conference is where the world meets cannabis. Find out more at InternationalCBC.com and on TwitterFacebook, and Instagram.